Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Cancer management in the Pacific region: a report on innovation and good practice.

Ekeroma A, Dyer R, Palafox N, Maoate K, Skeen J, Foliaki S, Vallely AJ, Fong J, Hibma M, Mola G, Reichhardt M, Taulung L, Aho G, Fakakovikaetau T, Watters D, Toliman PJ, Buenconsejo-Lum L, Sarfati D.

Lancet Oncol. 2019 Sep;20(9):e493-e502. doi: 10.1016/S1470-2045(19)30414-0. Epub 2019 Aug 5. Review.

PMID:
31395474
2.

The role of Langerhans cells in pathologies of the skin.

Rajesh A, Wise L, Hibma M.

Immunol Cell Biol. 2019 Sep;97(8):700-713. doi: 10.1111/imcb.12253. Epub 2019 May 8. Review.

PMID:
30989674
3.

Acceptability of self-taken vaginal HPV sample for cervical screening among an under-screened Indigenous population.

Adcock A, Cram F, Lawton B, Geller S, Hibma M, Sykes P, MacDonald EJ, Dallas-Katoa W, Rendle B, Cornell T, Mataki T, Rangiwhetu T, Gifkins N, Hart S.

Aust N Z J Obstet Gynaecol. 2019 Apr;59(2):301-307. doi: 10.1111/ajo.12933. Epub 2019 Jan 7.

PMID:
30614524
4.

Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016).

Innes CR, Sykes PH, Harker D, Williman JA, Van der Griend RA, Whitehead M, Hibma M, Lawton BA, Fitzgerald P, Dudley NM, Petrich S, Faherty J, Bergzoll C, Eva L, Sadler L, Simcock BJ.

Papillomavirus Res. 2018 Dec;6:77-82. doi: 10.1016/j.pvr.2018.10.010. Epub 2018 Nov 1.

5.

Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell response.

Zhang J, Burn C, Young K, Wilson M, Ly K, Budhwani M, Tschirley A, Braithwaite A, Baird M, Hibma M.

Sci Rep. 2018 Feb 5;8(1):2373. doi: 10.1038/s41598-018-20779-2.

6.

Suppression of the CD8 T cell response by human papillomavirus type 16 E7 occurs in Langerhans cell-depleted mice.

Jemon K, Leong CM, Ly K, Young SL, McLellan AD, Hibma MH.

Sci Rep. 2016 Oct 6;6:34789. doi: 10.1038/srep34789.

7.

Observational Management of CIN 2 in Young Women: A Prospective Multicenter Trial.

Sykes P, Innes C, Harker D, Whitehead M, van der Griend R, Lawton B, Hibma M, Fitzgerald P, Dudley N, Petrich S, Faherty J, Bergzoll C, Eva L, Parker C, Sadler L, Simcock B.

J Low Genit Tract Dis. 2016 Oct;20(4):343-7. doi: 10.1097/LGT.0000000000000244.

PMID:
27482796
8.

Langerhans cell homeostasis and activation is altered in hyperplastic human papillomavirus type 16 E7 expressing epidermis.

Abd Warif NM, Stoitzner P, Leggatt GR, Mattarollo SR, Frazer IH, Hibma MH.

PLoS One. 2015 May 18;10(5):e0127155. doi: 10.1371/journal.pone.0127155. eCollection 2015.

9.

An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.

Jemon K, Young V, Wilson M, McKee S, Ward V, Baird M, Young S, Hibma M.

PLoS One. 2013 Jun 14;8(6):e66866. doi: 10.1371/journal.pone.0066866. Print 2013.

10.

The immune response to papillomavirus during infection persistence and regression.

Hibma MH.

Open Virol J. 2012;6:241-8. doi: 10.2174/1874357901206010241. Epub 2012 Dec 28.

11.

Transcriptional repression of E-cadherin by human papillomavirus type 16 E6.

D'Costa ZJ, Jolly C, Androphy EJ, Mercer A, Matthews CM, Hibma MH.

PLoS One. 2012;7(11):e48954. doi: 10.1371/journal.pone.0048954. Epub 2012 Nov 26.

12.

Delivery of Echinococcus granulosus antigen EG95 to mice and sheep using recombinant vaccinia virus.

Dutton S, Fleming SB, Ueda N, Heath DD, Hibma MH, Mercer AA.

Parasite Immunol. 2012 Jun;34(6):312-7. doi: 10.1111/j.1365-3024.2012.01360.x.

13.

Predictors of intent to vaccinate against HPV/cervical cancer: a multi-ethnic survey of 769 parents in New Zealand.

Rose SB, Lawton BA, Lanumata TS, Hibma M, Baker MG.

N Z Med J. 2012 Feb 24;125(1350):51-62.

PMID:
22382257
14.

Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression.

D'Costa ZJ, Leong CM, Shields J, Matthews C, Hibma MH.

Invest New Drugs. 2012 Dec;30(6):2236-51. doi: 10.1007/s10637-012-9803-0. Epub 2012 Feb 23.

PMID:
22359217
15.

HPV/cervical cancer vaccination: parental preferences on age, place and information needs.

Rose SB, Lawton BA, Lanumata T, Hibma M, Baker MG.

J Prim Health Care. 2010 Sep 1;2(3):190-8.

PMID:
21069114
16.

Deregulation of E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types.

Leong CM, Doorbar J, Nindl I, Yoon HS, Hibma MH.

Br J Dermatol. 2010 Dec;163(6):1253-63. doi: 10.1111/j.1365-2133.2010.09968.x.

PMID:
20698848
17.

The orf virus inhibitor of apoptosis functions in a Bcl-2-like manner, binding and neutralizing a set of BH3-only proteins and active Bax.

Westphal D, Ledgerwood EC, Tyndall JD, Hibma MH, Ueda N, Fleming SB, Mercer AA.

Apoptosis. 2009 Nov;14(11):1317-30. doi: 10.1007/s10495-009-0403-1.

PMID:
19779821
18.

Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections.

Leong CM, Doorbar J, Nindl I, Yoon HS, Hibma MH.

J Invest Dermatol. 2010 Feb;130(2):472-80. doi: 10.1038/jid.2009.266. Epub 2009 Sep 17.

19.

Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells.

Hibma MH, Real NC, Wiles A, Dobson-Le D, Dix BR, Wynford-Thomas D, Braithwaite AW, Royds JA.

Virus Res. 2009 Oct;145(1):112-20. doi: 10.1016/j.virusres.2009.06.016. Epub 2009 Jul 2.

PMID:
19576936
20.

Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59.

Heinemann L, Woodfield L, Amer M, Hibma M.

Viral Immunol. 2008 Jun;21(2):225-33. doi: 10.1089/vim.2007.0101.

PMID:
18476769
21.

Self-applied treatment of persistent plantar wart with 5% imiquimod cream.

Leong CM, Tarbotton J, Hibma M.

N Z Med J. 2007 Aug 10;120(1259):U2668. No abstract available.

PMID:
17721576
22.

A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus.

Westphal D, Ledgerwood EC, Hibma MH, Fleming SB, Whelan EM, Mercer AA.

J Virol. 2007 Jul;81(13):7178-88. Epub 2007 May 2.

23.

Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2.

Dillon S, Sasagawa T, Crawford A, Prestidge J, Inder MK, Jerram J, Mercer AA, Hibma M.

J Gen Virol. 2007 Mar;88(Pt 3):803-13.

PMID:
17325352
24.

p53 promotes adenoviral replication and increases late viral gene expression.

Royds JA, Hibma M, Dix BR, Hananeia L, Russell IA, Wiles A, Wynford-Thomas D, Braithwaite AW.

Oncogene. 2006 Mar 9;25(10):1509-20.

PMID:
16247442
25.
26.

Flow cytometric quantitation of the protective efficacy of dendritic cell based vaccines in a human papillomavirus type 16 murine challenge model.

Heinemann L, Dillon S, Crawford A, Bäckström BT, Hibma MH.

J Virol Methods. 2004 Apr;117(1):9-18.

PMID:
15019255
27.

Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers.

Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, El-Sherif A, Morris L, Seth R, Hibma M, Jenkins D, Lambert P, Coleman N, Doorbar J.

J Virol. 2003 Oct;77(19):10186-201.

28.

Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin.

Matthews K, Leong CM, Baxter L, Inglis E, Yun K, Bäckström BT, Doorbar J, Hibma M.

J Virol. 2003 Aug;77(15):8378-85.

29.

Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

Edwards SJ, Dix BR, Myers CJ, Dobson-Le D, Huschtscha L, Hibma M, Royds J, Braithwaite AW.

J Virol. 2002 Dec;76(24):12483-90.

30.

Viruses to the rescue: p53-based therapies in the fight against cancer.

Hibma M, Braithwaite A.

N Z Med J. 2001 Jun 8;114(1133):266-9. Review. No abstract available.

PMID:
11453350
31.

The reactivity of monoclonal antibodies against orf virus with other parapoxviruses and the identification of a 39 kDa immunodominant protein.

Housawi FM, Roberts GM, Gilray JA, Pow I, Reid HW, Nettleton PF, Sumption KJ, Hibma MH, Mercer AA.

Arch Virol. 1998;143(12):2289-303.

PMID:
9930187
32.

The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cells.

Zatsepina O, Braspenning J, Robberson D, Hajibagheri MA, Blight KJ, Ely S, Hibma M, Spitkovsky D, Trendelenburg M, Crawford L, Tommasino M.

Oncogene. 1997 Mar 13;14(10):1137-45.

33.
34.

Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16.

Lehtinen M, Hibma MH, Stellato G, Kuoppala T, Paavonen J.

Biochem Biophys Res Commun. 1995 Apr 17;209(2):541-6.

PMID:
7733923
35.
36.

Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer.

Dillner J, Wiklund F, Lenner P, Eklund C, Frederiksson-Shanazarian V, Schiller JT, Hibma M, Hallmans G, Stendahl U.

Int J Cancer. 1995 Jan 27;60(3):377-82.

PMID:
7530234
37.

A non-radioactive assay for the detection and quantitation of a DNA binding protein.

Hibma MH, Ely SJ, Crawford L.

Nucleic Acids Res. 1994 Sep 11;22(18):3806-7. No abstract available.

38.

The influence of maternal separation on humoral and cellular immunity in farmed deer.

Hibma M, Griffin JF.

Brain Behav Immun. 1994 Mar;8(1):80-5.

PMID:
8003773
39.

The effect of adjuvants on active and passive immunity in pregnant deer and their offspring.

Hibma M, Griffin JF.

Vet Immunol Immunopathol. 1992 Mar;31(3-4):279-87.

PMID:
1589955
40.
41.

Epitope-mapped monoclonal antibodies against the HPV16E1--E4 protein.

Doorbar J, Ely S, Coleman N, Hibma M, Davies DH, Crawford L.

Virology. 1992 Mar;187(1):353-9.

PMID:
1371027
42.

The purification and characterisation of cervine IgM and IgG.

Hibma MH, Griffin JF.

Vet Immunol Immunopathol. 1990 Dec;26(4):343-52.

PMID:
2075697
43.

Altered humoral immunity during pregnancy in the guinea pig.

Hibma M, Griffin JF.

J Reprod Immunol. 1987 Apr;10(4):299-307.

PMID:
3625603

Supplemental Content

Support Center